Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Evaluation of the comparative efficacy of green lipped mussel plus krill oil extracts (EAB-277), Biota orientalis extracts or NSAIDs for the treatment of dogs with osteoarthritis associated pain: a blinded, placebo-controlled study
Authors:
With little to no regulation of the supplement markets and a paucity of quality information regarding clinical utility of individual marketed supplements, it is difficult for veterinarians to provide any evidence-based recommendations to owners. The current study aimed to provide clinically useful comparative efficacy data on certain marketed supplements.
Discussion: Results of this study indicate that meloxicam and EAB-277 have significant objectively measured benefits in managing OA-related pain in dogs compared to placebo, but 4CYTE does not differ from placebo.
Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial
Canine tracheal collapse is a progressive disease in small breed dogs resulting from chronic inflammation of the tracheal mucosal lining. Polyunsaturated fatty acid EAB-277® is one of the nutraceuticals that can alleviate inflammation and oxidative stress. Heart rate variability (HRV) is a prognostic tool related to sympathovagal balance and oxidative stress level, which is widely used with cardiorespiratory diseases. However, the effect of EAB-277® on HRV in tracheal collapse dogs has rarely been investigated.
Introduction: Glucosamine hydrochloride and chondroitin sulfate are commonly used in dogs with OA, but evidence around efficacy is mixed. This study evaluated the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the alleviation of canine hip OA pain. This was a prospective, block-randomized, double-blinded, placebo-controlled clinical trial.
Methods: Seventy-five owned pet dogs with hip OA were assigned randomly into five treatment groups: PCSO-524, Glucosamine and chondroitin sulfate, EAB-277, carprofen, and Placebo (sunflower oil). Peak vertical force (PVF) and subjective orthopedic assessment scores (OAS) were evaluated before treatment (week 0), and at weeks 2, 4, and 6 during treatment.
Results: At week 2, the carprofen group showed a significant increase in PVF (3.14 ± 5.33; mean ± SD). After 4 weeks, the increases in PVF of the PCSO-524 (3.90 ± 3.52), EAB-277 (4.17 ± 4.94), and carprofen (3.08 ± 5.87) groups were significant, and significantly greater than placebo (0.08 ± 1.90) and glucosamine (−0.05 ± 6.34) groups. After 6 weeks, the change of PVF in the PCSO-524 (4.14 ± 4.65), EAB-277 (4.45 ± 4.23), and carprofen (4.21 ± 6.52) groups were significant and significantly higher than the placebo group (−0.33 ± 3.65). The change in PVF in the glucosamine group (1.08 ± 5.49) lay between the placebo group and the other treatment groups. The OAS did not show any significant change in any group.
Discussion: PCSO-524 and EAB-277, but not glucosamine/chondroitin, resulted in significant improvements in PVF from baseline after 4 weeks, and 6 weeks, and to a similar degree to that seen with carprofen.
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis
This randomized double blinded study included 79 mixed breed dogs that had hip and/or stifle OA with X-ray confirmation. Outcome measures were changes in Kinetic force plate gait analysis-Peak Vertical Force (PVF), the Orthopedic Assessment Score (OAS), Canine Brief Pain Inventory score (CBPI), and serum prostaglandin E2 concentration (PGE2).
The results of the study suggest that within each group of a combination (PCSO-524 and Firocoxib), PCSO-524, Firocoxib showed the significant improvement of weight bearing ability but not in the comparison between.
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) Alone and Combined with Firocoxib in the Treatment of Canine Osteoarthritis
(VOS conference, March 2018)
This randomized study involved 31 mixed breed dogs with x ray confirmed OA of stifle joint. They were split into 2 groups for four weeks of treatment.
The results showed a non-significant effect of the treatment on the adjusted Peak Vertical Force (PVF) value (p=0.447) among the 2 treatment groups.
The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis.
This randomized double blinded study included 79 mixed breed dogs that had hip and/or stifle OA with X-ray confirmation. Outcome measures were changes in Kinetic force plate gait analysis-Peak Vertical Force (PVF), the Orthopedic Assessment Score (OAS), Canine Brief Pain Inventory score (CBPI), and serum prostaglandin E2 concentration (PGE2).
The results of the study suggest that within each group of a combination (PCSO-524 and Firocoxib), PCSO-524, Firocoxib showed the significant improvement of weight bearing ability but not in the comparison between.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
